A universal cure or definitive therapeutic regimen eliminating all major human cancers is approved by a major

Question

Six frontier AI models put this at 4% by 12 Oct 2076. Full reasoning from every model.

WillHappen.ai · Accepted Answer

4% — the median of 6 frontier models, resolving by 2076-10-12.

Answer

Gemini (Google): 4% — Cancer is hundreds of distinct diseases driven by divergent mutations, making a single universal therapy biologically implausible. The FDA and EMA require tumor-specific Phase III trial data, creating a regulatory hurdle no single pan-cancer drug has cleared. Immune evasion and genomic instability mean even broad-acting modalities like CAR-T or mRNA vaccines fail against many solid tumors. A foundational leap in broad-spectrum nanorobotics or pan-target gene editing is theoretically possible but decades from full clearance.

Answer

Claude (Anthropic): 3% — Cancer is hundreds of distinct diseases, so one universal approved cure is biologically implausible by 2050. No single mechanism targets all major cancer types given their vastly different drivers, mutations, and tissue biology. Current trends favor personalized combination therapies, not one universal cure, and FDA/EMA approvals are disease-specific by design. Major breakthroughs (CAR-T, checkpoint inhibitors) still only work for subsets of cancers, showing no sign of converging into a single cure.

Answer

GPT (OpenAI): 9% — This hinges on whether distinct cancer lineages prove to share a safely targetable curative vulnerability. FDA/EMA would need compelling durable survival data across common solid and blood cancers, likely from multi-year trials before 2050. No therapy has cured all major cancers; even transformative immunotherapies work in subsets, reflecting cancer's genetic and microenvironmental diversity. I would raise this sharply if a platform showed durable, broad cures in randomized trials across several high-incidence solid tumors by the 2030s.

Answer

Grok (xAI): 4% — Pan-cancer heterogeneity plus 24-year clock make a single approved universal regimen vanishingly unlikely. FDA/EMA would need a therapy proven curative across lung, breast, colorectal, pancreatic, glioma and others by ~2048. No historical analog exists; even CAR-T and checkpoint inhibitors remain type-specific after decades. A true pan-cancer CRISPR or neoantigen platform succeeding in Phase 3 would shift this, but none is near that bar.

Answer

DeepSeek (DeepSeek): 2% — Oncology's regulatory and biological reality makes a single pan-cancer cure approval before 2050 extremely unlikely. FDA and EMA approve drugs per indication, not per disease class, so no single approval can cover all major cancers. Even the most successful targeted therapies (imatinib in CML, CAR-T in leukemias) cure only narrow subsets; pan-cancer cures remain preclinical. A universal cure would require a mechanism killing every cancer lineage without lethal normal-tissue toxicity, which decades of research have not approached.

Answer

Qwen (Alibaba): 2% — Cancer is hundreds of distinct diseases; a single approved curative regimen across all major types is scientifically implausible by 2050. No therapy in history has cured even a majority of cancer types; checkpoint inhibitors and CAR-T each cover narrow subsets, and the heterogeneity of driver mutations… FDA/EMA approval for a single indication requires phase III trials lasting 5-10 years; demonstrating curative efficacy across all major cancers would require parallel… A development that would raise this above 5% would be a demonstrated pan-cancer mechanism (e.g., targeting a truly universal vulnerability) showing curative results in…

A universal cure or definitive therapeutic regimen eliminating all major human cancers is approved by a major regulatory agency before 2050.

What each one said

A universal cure or definitive therapeutic regimen eliminating all major human cancers is approved by a major regulatory agency before 2050.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.